How Deadly Is Ebola? Fatality Rates by Strain

Ebola’s deadliness depends heavily on which of the six known ebolaviruses causes the infection. A meta-analysis covering outbreaks from 1976 through 2022 found that the Zaire strain kills roughly two out of every three confirmed cases, while the Bundibugyo strain kills closer to one in three, and at least one strain has never caused a symptomatic human infection at all. Those numbers shift further depending on how quickly a patient reaches care, how old they are, and how much virus is circulating in their blood. The headline fatality figure most people associate with Ebola comes from its worst-case strain under worst-case conditions, and the full picture is more varied than the reputation suggests.

Zaire Ebolavirus Sets the Standard for Fear

Zaire ebolavirus (often just called “Ebola virus” or EBOV) is the strain behind every major headline-grabbing outbreak, including the catastrophic 2013–2016 West African epidemic and multiple outbreaks in the Democratic Republic of the Congo. Across all recorded outbreaks, a pooled analysis estimated its case fatality rate at about 67%.¹ Historically, though, the number has been higher. Early outbreaks in the 1970s and 1990s saw mortality exceed 80%, before modern supportive care and public health measures brought it down.² The wide range across outbreaks reflects real differences in healthcare infrastructure, speed of detection, and availability of treatment rather than changes in the virus itself.

The West African epidemic illustrates the swing dramatically. Early in the outbreak, case fatality rates in some areas topped 70%. As treatment centers scaled up and clinicians gained experience with aggressive fluid replacement and symptom management, that figure dropped to roughly 40%.³ The same virus, in the same population, killing at nearly half the rate once care improved. That gap is the single most important thing to understand about Ebola fatality statistics: the strain sets a ceiling, but the healthcare response determines where the actual number lands.

Sudan, Bundibugyo, and the Less Lethal Strains

Sudan ebolavirus (SUDV) is the second most dangerous strain to humans, with a pooled case fatality rate of about 49%.¹ The most recent Sudan virus outbreak, in Uganda in 2022, lasted 69 days and caused 164 cases with 77 deaths. That outbreak also showed stark age-related differences: children under 10 had a fatality rate of 75%, while adults between 40 and 49 died at about 62%.⁴ There is currently no approved vaccine for Sudan ebolavirus, which makes it a particular concern for outbreak preparedness since the existing rVSV-ZEBOV vaccine targets only Zaire.

Bundibugyo ebolavirus (BDBV), first identified in Uganda in 2007, is the least severe of the strains known to cause serious illness in people. The meta-analysis estimated its case fatality rate at roughly 33%.¹ In the original Bundibugyo outbreak, 17 of 43 laboratory-confirmed cases died, yielding a 40% fatality proportion. Symptoms were broadly similar to Zaire ebolavirus infections, with fever, fatigue, headache, vomiting, diarrhea, and muscle pain. Bleeding of some kind occurred in over half of confirmed patients. One notable finding was that difficulty swallowing was more common among patients who died, though only marginally so.⁵ A systematic review and meta-analysis confirmed Zaire as the most severe species and Bundibugyo as the least severe among those causing significant human disease.⁶

Strains That Barely Threaten Humans

Three ebolaviruses sit at the low end of the threat spectrum, though for different reasons. Taï Forest ebolavirus (TAFV) has caused exactly one known human infection, in a researcher who performed a necropsy on a dead chimpanzee in Côte d’Ivoire in 1994. She became seriously ill but survived, putting the human case fatality rate at 0% on a sample of one.¹ The confidence interval on that estimate is essentially meaningless (0 to 97.5%), given the sample size. Recent animal studies using ferrets have shown that Taï Forest virus can cause moderate to severe disease when exposure occurs through mucosal routes like the nasal passages rather than intramuscular injection, suggesting it has more pathogenic potential than the single human case might imply.⁷

Reston ebolavirus (RESTV) was first identified in 1989 when it killed imported macaques at a primate quarantine facility in Reston, Virginia. It causes severe disease in non-human primates but has never produced a symptomatic illness in a human. Workers exposed to the virus during that outbreak and subsequent ones in the Philippines seroconverted, meaning they developed antibodies confirming infection, but none got sick.⁸ The virus appears pathogenic in Asian monkeys but not in African monkeys or humans.⁹ Why Reston is harmless to us while its close relative Zaire is catastrophic remains only partly understood and is an active area of research.

Bombali ebolavirus (BOMV) is the most recently discovered species, identified in 2018 in free-tailed bats roosting inside houses in Sierra Leone.¹⁰ No human infections have been confirmed. Laboratory work shows that while Bombali’s surface protein can bind to human cells, it does so inefficiently. Researchers using mice engineered with human-like immune systems found that Bombali showed low pathogenicity comparable to Reston.¹¹ However, laboratory experiments have shown that only a few mutations in Bombali’s surface protein could significantly boost its ability to enter human cells, making ongoing surveillance of this virus a priority.¹²

What Actually Determines Whether a Patient Survives

Within any given strain and outbreak, individual survival varies enormously, and the strongest predictor is how much virus is in the patient’s blood. A study of 288 Ebola patients found that those with viral loads above a million copies per milliliter had triple the odds of dying compared to those with lower viral loads.¹³ A separate analysis put numbers on the gradient more precisely: in the first week after symptom onset, patients with low viremia had about a 21% fatality rate, those with intermediate levels had about 53%, and those with high viremia faced roughly 81%.¹⁴ Viral load at admission essentially sorts patients into different risk categories regardless of which treatment center they are in.

Age also matters. In the same study of 288 patients, age correlated with mortality independently of viral load, with older patients doing worse.¹³ Data from Ebola-affected households in Sierra Leone showed the pattern in more detail: children aged 5 to 14 had the lowest risk of developing disease at all, while children under 2 and adults over about 35 faced higher risk.¹⁵ The presence of diarrhea at admission has also been linked to worse outcomes, likely because severe fluid loss accelerates the organ failure that makes Ebola lethal.

At the immune level, the difference between survivors and fatalities comes down to whether the body mounts a controlled response or spirals into inflammatory chaos. Survivors tend to produce antibodies against the virus early and sustain them, followed by activation of virus-killing T cells. Fatalities show the opposite pattern: an impaired antibody response and early T cell activation that collapses as the virus triggers widespread cell death in the immune system.¹⁶ Research comparing fatal and surviving patients from the West African outbreak found that patients who died had a runaway inflammatory response, with dozens of inflammatory molecules spiking higher and higher as the disease progressed, while survivors showed a more measured pattern.¹⁷

Pregnancy Dramatically Worsens the Odds

Ebola during pregnancy is a particularly grim scenario. Historical reports from Zaire ebolavirus outbreaks placed maternal mortality between 74% and 100%, and a literature review found aggregate maternal mortality of 86% across 111 reported cases.¹⁸ More recent data from the West African epidemic suggested outcomes may not always be quite that extreme, but the numbers are still dire. A systematic review estimated the absolute risk of maternal death at about 68%.¹⁹

For the fetus, the outcome is almost always fatal. The same review estimated fetal losses at about 77% and neonatal death at close to 99%.¹⁹ A study from Sierra Leone found that pregnant women with confirmed Ebola had ten times the odds of dying compared to women in the same isolation units who tested negative. Among live births to Ebola-positive mothers, five of six newborns died.²⁰ The virus can pass from mother to fetus during pregnancy, during delivery, or through breast milk afterward, making the developing fetus extraordinarily vulnerable.

How Treatment Has Bent the Curve

The most significant factor in lowering Ebola’s effective fatality rate has been the improvement in supportive care rather than any single antiviral drug. The basics, replacing lost fluids and electrolytes, managing fever, treating secondary infections, and monitoring organ function, account for much of the mortality reduction seen over the past decade.²¹ A comparison of two Ebola treatment centers in Sierra Leone found that patients treated at a facility offering intensive-care-level support had more hospital-free days and a trend toward lower mortality than those at a center with standard care.²²

On the drug side, progress has been slower than the headlines might suggest. The monoclonal antibody cocktail ZMapp was the first therapy tested in a proper randomized trial, but that trial enrolled only 72 patients and produced a mortality difference that was not statistically significant (about 22% with ZMapp versus 37% with standard care).²³ Since then, two monoclonal antibody treatments, mAb114 (Ebanga) and REGN-EB3 (Inmazeb), have been approved for Zaire ebolavirus. These showed survival benefits in a trial during the DRC’s 2018–2020 outbreak, particularly when given early. But they only target Zaire, leaving Sudan and Bundibugyo without specific therapies.

The Reported Death Rate Is Probably an Overestimate

Every case fatality figure cited so far comes with an important caveat: they are calculated from people who were sick enough to be identified as cases. People who contract Ebola and experience no symptoms or only mild illness never show up in the numerator or denominator of outbreak statistics. A BMJ analysis pointed out that if even half of infections go undetected, the true fatality rate of infection would be about half the reported case fatality rate.²⁴

Evidence that asymptomatic Ebola infection exists comes from seroprevalence studies, where researchers test people who were exposed to the virus but never got visibly sick. A study of contacts of Ebola patients in Guinea found enough asymptomatic and mildly symptomatic infections to conclude that the reported case fatality rate of 67% in Guinea overestimated the true infection fatality rate.²⁵ How much lower the true rate is remains genuinely uncertain. What is clear is that the numbers published during outbreaks represent the fatality rate among recognized, typically severe cases, not the fatality rate among everyone infected.

Viral Mutations and Their Effect on Lethality

A natural question is whether Ebola is evolving to become more or less lethal. The evidence so far is mixed and tentative. During the West African epidemic, researchers tracked a mutation in the virus’s surface protein called GP-A82V. People infected with virus carrying this mutation had about 2.6 times the odds of dying compared to those infected with the ancestral genotype. Even after adjusting for viral load and geographic variation in healthcare access, the odds ratio stayed above 1, though the confidence interval widened enough that the researchers could not rule out the possibility of no independent effect.²⁶ The mutation appeared to increase the virus’s ability to enter human cells, which could partly explain the association.

A separate analysis took a different approach, looking not at individual mutations but at networks of co-occurring mutations across the whole viral genome. The number of any single mutation did not correlate with fatality rates. But the complexity of the mutation network, how many interacting co-mutations existed, showed a striking negative correlation with lethality. In other words, outbreaks where the virus had accumulated more complex patterns of co-mutations tended to have lower case fatality rates.²⁷ This is a finding from a single research group and should be treated cautiously, but it hints that viral evolution during prolonged outbreaks may trend toward lower virulence, which would be consistent with a general evolutionary principle: a pathogen that kills its host too quickly has fewer chances to spread.

How Ebola Kills

The fatality rates across strains ultimately reflect differences in how aggressively each variant dismantles the body’s systems. Ebola targets immune cells called macrophages and dendritic cells early in infection, using them as vehicles to spread to the liver, spleen, and lymph nodes. The virus attacks organs responsible for regulating fluid balance and blood clotting, and causes the liver, lungs, and kidneys to progressively shut down. Blood vessels begin leaking fluid into surrounding tissues, contributing to the shock and multi-organ failure that account for most deaths.²⁸ The bleeding that gives Ebola its popular nickname “hemorrhagic fever” is real but not always the dominant feature. In the Bundibugyo outbreak, for example, about 54% of confirmed patients experienced some form of bleeding, but many died from organ failure without dramatic external hemorrhage.⁵

Surviving Ebola Does Not Mean It Is Over

Even patients who survive acute Ebola can face serious consequences afterward. The virus is capable of persisting in immune-privileged sites, areas of the body where the immune system is less active, including the eyes, central nervous system, and reproductive tract. In a case documented during the 2018–2020 DRC outbreak, a male survivor who had been treated with monoclonal antibodies relapsed with severe Ebola-like illness six months after his initial recovery and died. Genomic investigations confirmed it was a true relapse rather than a new infection, and the relapse sparked a new transmission chain of 91 cases across six health zones over four months.²⁹

Research in non-human primates has illuminated a possible mechanism. In macaques that survived Ebola infection after monoclonal antibody treatment, the virus was cleared from every organ except the brain’s ventricular system, where it persisted in immune cells called macrophages. The persistence was accompanied by severe inflammation, including damage to the membranes lining the brain’s fluid-filled cavities. Some of these treated survivors went on to develop fatal brain-confined relapses.³⁰ The finding raises uncomfortable questions about whether antibody-based therapies, while life-saving during acute infection, may inadvertently drive viral persistence in sites the antibodies cannot easily reach. It also means that the true toll of an Ebola outbreak extends beyond the initial case count, since survivors can reignite transmission months later.

Healthcare Workers Face a Different Kind of Risk

Outbreaks of Ebola among healthcare workers have historically served as early warning signals that a new epidemic is underway, since hospital and clinic staff are often among the first exposed before the disease is recognized. Nosocomial spread between staff and patients can amplify an outbreak and carry it back into the surrounding community.³¹ A common assumption is that healthcare workers die at higher rates because of heavier viral exposure, but a meta-analysis found that the odds of an infected healthcare worker dying were not significantly different from those of non-healthcare patients.³² Their risk is primarily one of exposure, not of worse outcomes once infected. That distinction matters for outbreak planning: protecting healthcare workers is about preventing infections through proper equipment and protocols rather than about providing fundamentally different treatment once they fall ill.

1
PubMed. Case fatality rate for Ebola disease, 1976-2022: A meta-analysis of global data
2
PubMed Central. An overview of Ebola virus disease
3
The Lancet. Optimal supportive care for managing patients with Ebola virus disease in treatment centres
4
Emerging Infectious Diseases. Modeling Case Burden and Duration of Sudan Ebola Virus Disease Outbreak in Uganda, 2022
5
PubMed Central. Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda
6
PubMed Central. How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence
7
PLOS Pathogens. Mucosal Taï Forest virus infection causes disease in ferrets
8
Journal of One Health, Veterinary and Allied Sciences. Reston Ebolavirus: Decoding the Non-Pathogenic Enigma among Deadly Filoviruses
9
PubMed. Current knowledge on lower virulence of Reston Ebola virus
10
PubMed Central. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses
11
PubMed Central. In vivo characterization of the novel ebolavirus Bombali virus suggests a low pathogenic potential for humans
12
hLife. Assessing risk of Bombali virus spillover to humans by mutagenesis analysis of viral glycoprotein
13
PubMed Central. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients
14
PLOS Medicine. Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort Study
15
PubMed Central. Exposure-Specific and Age-Specific Attack Rates for Ebola Virus Disease in Ebola-Affected Households, Sierra Leone
16
Frontiers in Immunology. Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection
17
PubMed Central. Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014–2016 Outbreak in West Africa
18
PubMed Central. Ebola virus disease and pregnancy: a systematic review and meta-analysis
19
Transactions of The Royal Society of Tropical Medicine and Hygiene. Ebola virus disease in pregnancy: a systematic review and meta-analysis
20
PubMed Central. Maternal and perinatal outcomes in pregnant women with suspected Ebola virus disease in Sierra Leone
21
PubMed Central. Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo
22
PubMed Central. Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa
23
PubMed Central. Anti-Ebola therapy for patients with Ebola virus disease: a systematic review
24
PubMed. Under-reporting and case fatality estimates for emerging epidemics
25
The Lancet Infectious Diseases. Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study
26
Cell. Human Adaptation of Ebola Virus during the West African Outbreak
27
Cell Research. Network of co-mutations in Ebola virus genome predicts the disease lethality
28
Cell Death & Differentiation. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death
29
PubMed Central. Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease
30
PubMed. Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors
31
The Journal of Infectious Diseases. Infection Rates and Risk Factors for Infection Among Health Workers During Ebola and Marburg Virus Outbreaks: A Systematic Review
32
International Journal of Innovative Research and Scientific Studies. Cross-continental burden of Ebola hemorrhagic fever: A meta-analytical comparison, prevalence, mortality, and risk factors